Medication reconciliation is commonly positioned at admission and discharge as a central defence against medication error during transitions of care. Its value is well established for reconstructing medication histories, identifying discrepancies, clarifying undocumented changes, and improving the accuracy of medication information transferred between settings. Yet clinically important pharmacotherapy risk is not generated only when medication lists disagree. Patients may reach hospital with unstable treatment, high-risk medicines, polypharmacy, frailty, unresolved adverse effects, adherence difficulty, or monitoring deficits. Hospitalization can then deliberately alter the regimen, creating new treatment intentions, surveillance requirements, communication tasks, and practical demands that persist after discharge. Evidence showing substantial reductions in medication errors without corresponding reductions in short-term healthcare utilization illustrates why medication-list accuracy and longitudinal medication safety should not be treated as interchangeable outcomes. Reconciliation can be understood as one time-specific intervention within a longer pharmacotherapy-risk trajectory. This perspective distinguishes preadmission instability, transition-generated discrepancies, intended inpatient treatment changes, unresolved treatment intent, monitoring obligations, information continuity, and the patient's capacity to enact a changed regimen during recovery. Reconciliation remains indispensable where the problem is inaccurate or discordant medication information. Its reach is narrower when risk arises from prescribing decisions, inadequate monitoring, insufficient explanation, weak follow-up, or difficulties implementing treatment after discharge. A more informative medication-safety strategy therefore asks not only whether lists agree, but which risks remain active, who is responsible for resolving them, and whether the next care environment can complete the work initiated in hospital.
